Cancer

Mouse studies suggest inhibiting ADAM10 with INCB7839 could help treat brain cancer. In a mouse model of high-grade glioma, knockout of NLGN3 -- which is activated by ADAM10-mediated cleavage from synaptic membranes -- decreased tumor growth compared with normal NLGN3 expression. In a mouse model of pediatric glioblastoma, the dual ADAM10/ADAM17 inhibitor INCB7839 decreased tumor growth compared with vehicle. Next steps in collaboration with Incyte Corp. could include clinical testing of INCB7839 in high-grade glioma...